News

Canon has launched new TAVR technology designed to help structural heart programs address increasing procedural demand. No specific clinical data or device specifications were provided in the announcement.

Digest: New imaging or support technology from Canon could enhance procedural efficiency and capacity as TAVR volumes continue to expand across risk categories.

CMS is considering coverage for transcatheter aortic valve replacement (TAVR) in patients with aortic regurgitation. This would represent a significant expansion beyond the current approved indication of aortic stenosis.

Digest: CMS coverage for TAVR in aortic regurgitation would open a new market segment and provide reimbursement for an off-label use that has shown feasibility in selected patients but lacks robust trial data.

The FDA has approved the first pediatric heart valve prosthesis designed to grow with children as they develop. This represents a significant advancement in congenital valve replacement, potentially reducing the number of reoperations required in pediatric patients.

Digest: This approval addresses a critical unmet need in pediatric structural heart disease by eliminating the requirement for multiple valve replacements as children grow, which could substantially reduce surgical burden and improve long-term outcomes.

The FDA has granted clearance for a video endoscope system intended for use in select minimally invasive cardiac surgical procedures. Specific procedural indications and device specifications were not detailed in the available content.

Digest: Enhanced visualization technology for minimally invasive cardiac surgery may facilitate adoption of less invasive surgical approaches for structural heart interventions, particularly minimally invasive surgical valve repair and replacement.

The FDA cleared an artificial intelligence tool designed to detect undiagnosed valvular heart disease through analysis of standard 12-lead electrocardiograms. The AI algorithm enables screening for structural heart conditions using routine ECG data without requiring echocardiography.

Digest: This screening tool could facilitate earlier identification of valve disease patients who may be candidates for structural heart interventions, potentially expanding the treatable patient population.

Women experience persistent mitral regurgitation following transcatheter aortic valve replacement at higher rates compared to men. This sex-based difference in post-TAVR outcomes suggests potential anatomical or procedural factors affecting mitral valve function differently between sexes.

Digest: Sex-specific differences in post-TAVR complications may influence patient selection, procedural planning, and surveillance protocols for structural heart teams performing TAVR procedures.

Patients who wait longer than 6 months to undergo transcatheter aortic valve replacement after indication may experience worse survival outcomes. The study suggests timely TAVR referral and performance is associated with improved mortality rates compared to prolonged delays.

Digest: This finding reinforces the importance of streamlined TAVR referral pathways and may influence heart team decision-making regarding procedural timing and patient selection strategies.

Photon-counting CT has been validated as an accurate screening tool for detecting valve dysfunction in patients who have undergone transcatheter aortic valve replacement. The imaging modality demonstrates improved diagnostic capability for assessing TAVR valve performance during follow-up.

Digest: Advanced imaging tools that can reliably detect early TAVR valve dysfunction are critical for optimizing long-term patient management and surveillance strategies as TAVR extends into younger, lower-risk populations.

TCT 2026 conference organizers have announced the slate of late-breaking clinical trials to be presented in San Diego. The announcement indicates which studies will be featured, though specific trial names and data are not yet disclosed.

Digest: Late-breaking trial announcements at TCT typically include pivotal structural heart studies that influence clinical practice and regulatory decisions in the interventional cardiology field.

Medical societies and aging advocacy groups have issued initial responses to new CMS coverage policies affecting transcatheter aortic valve replacement. The policy changes appear to modify reimbursement or coverage criteria for TAVR procedures.

Digest: CMS coverage determinations directly impact TAVR access, reimbursement dynamics, and patient selection strategies for structural heart programs nationwide.

CMS finalized a national coverage determination expanding Medicare coverage for transcatheter aortic valve replacement to include asymptomatic patients with severe aortic stenosis. This represents a significant broadening of the Medicare eligible patient population beyond the previous requirement for symptomatic disease.

Digest: This reimbursement expansion substantially increases the addressable market for TAVR and aligns Medicare coverage with current clinical practice patterns and recent trial evidence in asymptomatic severe AS patients.

The FDA has granted clearance for a new embolic protection device designed to capture debris during transcatheter aortic valve replacement procedures. This device aims to reduce the risk of periprocedural stroke by preventing particulate matter from reaching the cerebral circulation during valve deployment.

Digest: Embolic protection devices address a persistent clinical concern in TAVR, as stroke remains a significant complication affecting 1-3% of procedures and impacting patient outcomes and healthcare costs.

New data reveal ongoing concerns about heart failure occurrence both before and after transcatheter aortic valve replacement procedures. The findings highlight persistent clinical challenges in managing heart failure in TAVR patient populations.

Digest: Heart failure remains a critical complication affecting TAVR outcomes and patient selection, with implications for pre-procedural optimization and post-procedural surveillance strategies.

A surgeon completed the first implant of a semi-rigid annuloplasty ring for tricuspid valve repair. No additional clinical details, outcomes, or patient data were provided in the source material.

Digest: Represents a technical milestone in surgical tricuspid valve repair, though clinical significance cannot be assessed without device specifications, patient outcomes, or comparative data.

A cardiac surgeon performed the first US implant of an investigational heart valve device that is currently undergoing FDA review but has not yet received regulatory approval. The procedure represents an early access case under what is likely an FDA early feasibility study or expanded access protocol.

Digest: This signals advancement of a novel valve technology through US regulatory pathways and provides early clinical experience that may inform future FDA approval decisions and market adoption strategies.

Medtronic announced an investment of up to $80 million in Pi-Cardia, a medical technology company, with a potential acquisition option included in the agreement. No specific clinical data or device performance metrics were disclosed in this announcement.

Digest: This strategic investment signals Medtronic's interest in expanding its structural heart portfolio through potential acquisition of Pi-Cardia's technology platform.

Tricuspid valve repair demonstrated major clinical benefits in high-risk patients with significant tricuspid regurgitation. The study showed improved outcomes in this challenging patient population undergoing intervention.

Digest: Establishes evidence for tricuspid intervention in high-risk cohorts, supporting growing adoption of transcatheter and surgical repair techniques in an underserved valve disease population.

The article addresses the clinical question of optimal sequencing when patients require both transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI). The content explores whether performing PCI before, during, or after TAVR affects procedural outcomes and patient safety.

Digest: Concomitant coronary artery disease is common in TAVR candidates, and determining the optimal revascularization strategy impacts procedural planning, resource allocation, and patient outcomes for interventional cardiologists.

An analysis found no significant sex-based differences in timing of care for patients undergoing mitral transcatheter edge-to-edge repair (M-TEER). The study suggests that male and female patients receive similarly timed treatment access and procedural care.

Digest: Demonstrates equity in care delivery for M-TEER procedures across sexes, addressing ongoing concerns about potential gender disparities in access to advanced structural heart interventions.

A new risk scoring system has been developed to predict poor functional outcomes in older patients undergoing transcatheter aortic valve replacement. The score aims to improve patient selection and prognostication beyond traditional mortality risk assessments.

Digest: This tool could help structural heart teams better identify elderly TAVR candidates at risk for diminished quality of life or functional decline post-procedure, potentially improving shared decision-making and patient selection.

A study reports early positive outcomes in patients undergoing redo transcatheter aortic valve replacement procedures using self-expanding valve prostheses. The findings suggest self-expanding valves may be a viable option for treating failed prior TAVR procedures.

Digest: This addresses a growing clinical challenge as the first generation of TAVR patients develop structural valve deterioration requiring reintervention, informing valve selection strategies for redo procedures.

A New York health system filed a lawsuit against another health system over cardiology services, escalating competition for cardiovascular care delivery in the region. The legal dispute prompted state legislators to introduce new legislation addressing healthcare service agreements and competition.

Digest: Litigation over cardiology service lines reflects intensifying competition for structural heart programs, which may impact referral patterns, program consolidation, and access to TAVR and other interventional procedures in competitive markets.

A study demonstrates that transcatheter aortic valve replacement is safe in patients with large aortic annuli. Heart failure complications remain an area of concern in this patient population.

Digest: Expands evidence for TAVR applicability in anatomically challenging cases with larger annular dimensions, though persistent heart failure risk may influence device selection and patient management strategies.

New data demonstrate superior outcomes for surgical aortic valve replacement (SAVR) compared to transcatheter aortic valve replacement (TAVR) in younger patients with aortic stenosis. The findings reinforce current clinical guidance favoring surgery over TAVR in younger, lower-risk patient populations.

Digest: These results support treatment allocation strategies and reinforce age-based selection criteria that impact procedural volumes and market share between TAVR platforms and surgical valve programs.

An AI-powered opportunistic screening tool is being developed to identify patients with undiagnosed aortic stenosis using existing imaging data. The technology aims to detect asymptomatic or unrecognized cases by analyzing routine medical scans that were performed for other clinical indications.

Digest: Early detection of aortic stenosis through opportunistic AI screening could identify intervention candidates before symptom onset, potentially improving outcomes and expanding the patient pool for TAVR and SAVR procedures.

Banner Health is partnering with physicians to expand cardiovascular procedures in ambulatory surgery centers. The initiative aims to shift appropriate heart procedures from hospital-based settings to lower-cost ASC environments.

Digest: ASC migration of structural heart procedures could impact reimbursement models and site-of-service strategies as health systems seek cost reduction while maintaining quality outcomes.

Cardiologists have developed a novel anchoring technique to address challenging anatomical scenarios in transcatheter aortic valve replacement procedures. The technical innovation aims to improve procedural outcomes in complex TAVR cases where conventional deployment methods may be inadequate.

Digest: Procedural technique refinements for anatomically challenging cases may expand TAVR eligibility and reduce complications in high-risk subgroups such as those with hostile anatomy or severe calcification.

Emerging developments in cardiac CT include artificial intelligence-driven preventive imaging strategies and noncontrast imaging techniques. These advances aim to expand cardiac CT's clinical utility beyond current anatomical assessment capabilities.

Digest: Enhanced cardiac CT capabilities could improve preprocedural planning for structural heart interventions and risk stratification without contrast-related complications.

Incidental findings on pre-procedural CT scans demonstrate predictive value for mortality following transcatheter aortic valve replacement. The study suggests that non-cardiac imaging findings identified during routine TAVR planning may provide additional risk stratification capabilities.

Digest: Integration of incidental CT findings into TAVR risk assessment models could improve patient selection and prognostic accuracy beyond traditional cardiac risk scores.

The FDA has confirmed a new recall affecting accessories used with Abiomed's Impella percutaneous ventricular assist device system. Specific details regarding the affected accessory components, reason for recall, and adverse event data were not provided in the available article content.

Digest: Impella devices are widely used for hemodynamic support during high-risk PCI and cardiogenic shock management, making any recall of associated accessories clinically relevant for procedural safety and device availability.

An expert panel discussion examined current state and future directions of transcatheter aortic valve replacement technology and clinical practice. The panel format suggests coverage of evolving TAVR techniques, patient selection, and emerging challenges in the field.

Digest: Panel discussions at this stage of TAVR adoption typically address unresolved clinical questions around patient selection, durability, and expansion into lower-risk populations that guide practice patterns.

Economic analysis suggests early transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis may be cost-effective compared to watchful waiting. The cost savings would accrue from preventing heart failure hospitalizations and complications associated with delayed intervention.

Digest: This health economics data could influence coverage decisions and clinical practice patterns by supporting intervention before symptom onset in severe AS patients.

New data from the PARTNER 3 trial demonstrate early clinical benefits of transcatheter aortic valve replacement (TAVR) compared to surgical aortic valve replacement (SAVR) in low-risk patients. The updated analysis reinforces TAVR's favorable early outcomes in this patient population.

Digest: These findings support expanding TAVR utilization in low-risk surgical candidates and may influence treatment algorithms and guideline recommendations for aortic stenosis management.

A biomarker enzyme ratio shows potential for predicting stroke and atrial fibrillation risk following transcatheter aortic valve replacement. The diagnostic tool could enable cardiologists to identify high-risk TAVR patients requiring enhanced monitoring or prophylactic intervention.

Digest: Risk stratification biomarkers for post-TAVR cerebrovascular and arrhythmic complications could improve patient selection, personalize antithrombotic strategies, and reduce adverse events in an expanding TAVR population.

Abbott is collecting real-world data on its TriClip transcatheter tricuspid valve repair system following FDA approval. The post-market data collection will provide insights into clinical outcomes and device performance outside of controlled trial settings.

Digest: Real-world evidence will be critical for understanding TriClip performance in broader patient populations and supporting clinical adoption in the emerging transcatheter tricuspid repair market.

A new study examines failure to rescue rates following transcatheter aortic valve replacement (TAVR) procedures, comparing outcomes between high-volume and low-volume hospital centers. The analysis focuses on hospital-level differences in mortality following post-procedural complications.

Digest: Failure to rescue metrics may inform hospital volume-outcome relationships and quality benchmarking for TAVR programs, with implications for center credentialing and patient referral patterns.

A study found that less invasive anesthesia strategies during transcatheter aortic valve replacement are associated with improved clinical outcomes. The use of conscious sedation or local anesthesia instead of general anesthesia during TAVR procedures demonstrated a key benefit for patients.

Digest: Anesthesia strategy optimization represents a modifiable procedural factor that can improve TAVR outcomes and potentially reduce costs without requiring changes to valve technology or operator technique.

Medical societies are publicly responding to a CMS proposal regarding TAVR coverage as the agency approaches its final decision. The societies' positions indicate stakeholder engagement on potential changes to reimbursement or coverage criteria for transcatheter aortic valve replacement.

Digest: CMS coverage decisions directly impact patient access to TAVR and procedural volumes at structural heart programs, particularly if eligibility criteria or site-of-service requirements change.

An article discusses how artificial intelligence can assist heart teams in identifying appropriate patients for transcatheter aortic valve replacement. No specific AI platform, clinical data, or implementation details were provided in the available content.

Digest: AI-driven patient identification tools could improve TAVR referral patterns and reduce undertreatment of severe aortic stenosis, though clinical validation and implementation strategies remain unclear from this report.

A cardiac surgeon performed the first robotic-assisted structural heart procedure of an unspecified type, representing a technical milestone in minimally invasive cardiac intervention. No clinical outcomes, procedural details, or patient data were provided in the available content.

Digest: Robotic platforms may expand minimally invasive options for structural heart procedures, though clinical efficacy and safety data are needed to assess impact on practice patterns.

Recent clinical data demonstrate long-term structural valve durability outcomes for transcatheter aortic valve replacement (TAVR) procedures. The findings provide cardiologists with evidence regarding hemodynamic performance and structural valve deterioration rates at extended follow-up intervals.

Digest: Long-term durability data are critical for informing TAVR patient selection, particularly in younger and lower-risk populations where valve longevity directly impacts lifetime management strategies.

A study identifies a simple biomarker that can predict which patients are at high risk for acute kidney injury following transcatheter aortic valve replacement. The biomarker enables cardiologists to stratify risk and potentially modify perioperative management in vulnerable TAVR patients.

Digest: Acute kidney injury is a significant complication after TAVR associated with increased morbidity and mortality, and preprocedural risk stratification could enable targeted renal protective strategies in high-risk patients.

Medtronic has issued a recall of a heart valve delivery system due to an identified safety risk. Specific details regarding the affected device model, nature of the safety concern, patient impact, and scope of the recall were not provided in the available content.

Digest: Device recalls can impact procedural planning and inventory management for structural heart programs, and may signal potential adverse events requiring vigilance in patients who received the affected system.

Cardiologists report early favorable outcomes using a leaflet modification device to facilitate valve-in-valve TAVR procedures. The device appears to address challenges associated with coronary obstruction risk during ViV-TAVR interventions.

Digest: Leaflet modification techniques may expand treatment options for patients with failed surgical bioprostheses by reducing coronary obstruction risk, a major limitation of valve-in-valve TAVR.

New follow-up data from the EARLY TAVR trial demonstrate continued clinical benefits of transcatheter aortic valve replacement in patients with asymptomatic severe aortic stenosis. The updated results reinforce the safety and efficacy of early intervention before symptom onset in this patient population.

Digest: These findings support expanding TAVR utilization to asymptomatic patients with severe AS, potentially shifting treatment paradigms and increasing the addressable patient population for structural heart programs.

Transcatheter aortic valve replacement using an Edwards Lifesciences valve system demonstrated encouraging outcomes in patients with severe aortic regurgitation. The data suggest TAVR may be a viable treatment option for this traditionally surgical patient population.

Digest: Severe AR has been a relative contraindication for TAVR due to anatomical challenges, and positive data could expand the treatment population and market for Edwards' valve technology.

A new meta-analysis examined sex-specific outcomes in patients undergoing transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR). The analysis revealed differential outcomes between male and female patients across the two treatment modalities.

Digest: Understanding sex-based differences in TAVR and SAVR outcomes can inform patient selection, procedural planning, and shared decision-making for aortic stenosis treatment.

A high-intensity ultrasound technology designed to treat calcified valve leaflets has launched in Europe. No specific clinical data or device details were provided in the article content.

Digest: Novel leaflet modification technologies could expand treatment options for calcified valves, though clinical validation data are needed to assess utility in structural heart interventions.

CMS proposed significant policy changes affecting TAVR reimbursement and coverage, prompting responses from interventional cardiologists and cardiac surgeons. The clinical and financial implications of these proposed modifications are being evaluated by the structural heart community.

Digest: CMS reimbursement policy directly impacts TAVR program sustainability, patient access, and the economic viability of structural heart programs nationwide.

A family filed a $17 million lawsuit alleging that a heart valve was implanted upside down in a young girl during cardiac surgery. The complaint suggests surgical error resulting in improper valve orientation and subsequent patient harm.

Digest: Surgical valve orientation errors, while rare, represent a critical quality and safety concern that can lead to valvular dysfunction, reoperation, and medico-legal implications for cardiac surgery programs.